Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 15/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24125956 | 1.00 | DDB1 (0.54) | DDB1CRBNS1PR1APPIKZF2 | |
| SCHEMBL24124617 | 1.00 | DDB1 (0.54) | DDB1CRBNS1PR1APPIKZF2 | |
| Hydrochloric Acid SCHEMBL23301328 | 0.99 | DDB1 (0.53) | DDB1CRBNS1PR1APPIKZF2 | |
| Hydrochloric Acid SCHEMBL23301327 | 0.99 | DDB1 (0.53) | DDB1CRBNS1PR1APPIKZF2 | |
| Trifluoroacetic Acid SCHEMBL25167571 | 0.94 | DDB1 (0.48) | DDB1CRBNS1PR1IKZF2 | |
| Trifluoroacetic Acid SCHEMBL25169720 | 0.94 | DDB1 (0.48) | DDB1CRBNS1PR1IKZF2 | |
| SCHEMBL23301372 | 0.89 | S1PR1 (0.54) | DDB1CRBNS1PR1 | |
| SCHEMBL24126179 | 0.89 | S1PR1 (0.54) | DDB1CRBNS1PR1 | |
| SCHEMBL24126164 | 0.87 | DDB1 (0.50) | DDB1CRBNS1PR1 | |
| SCHEMBL25175404 | 0.87 | DDB1 (0.53) | DDB1CRBNIKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | DDB1 425/4885CRBN 32/4885S1PR1 901/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | DDB1 368/4885CRBN 249/4885S1PR1 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.